Oncolytic virotherapy

Oncolytic adenovirus and gene therapy with EphA2-BiTE for the treatment of pediatric high-grade gliomas
Claudia Manuela Arnone, Vinicia Assunta Polito, Angela Mastronuzzi, Andrea Carai, Francesca Camassei Diomedi, Laura Antonucci, Lucia Lisa Petrilli, Maria Vinci, Francesco Ferrari, Elisa Salviato, Marco Scarsella, Cristiano De Stefanis, Gerrit Weber, Concetta Quintarelli, Biagio De Angelis, Malcolm K Brenner, Stephen Gottschalk, Valentina Hoyos, Franco Locatelli, Ignazio Caruana, Francesca Del Bufalo

Journal for ImmunoTherapy of Cancer May 2021, 9 (5) e001930; DOI: 10.1136/jitc-2020-001930
The use of oncolytic virotherapy in the neoadjuvant setting
Raquela J Thomas, Eric Bartee

Journal for ImmunoTherapy of Cancer Apr 2022, 10 (4) e004462; DOI: 10.1136/jitc-2021-004462
OrienX010, an oncolytic virus, in patients with unresectable stage IIIC–IV melanoma: a phase Ib study
ChuanLiang Cui, Xuan Wang, Bin Lian, Qing Ji, Li Zhou, Zhihong Chi, Lu Si, Xinan Sheng, Yan Kong, Jiayi Yu, Siming Li, Lili Mao, Bixia Tang, Jie Dai, Xieqiao Yan, Xue Bai, Robert Andtbacka, Jun Guo

Journal for ImmunoTherapy of Cancer Apr 2022, 10 (4) e004307; DOI: 10.1136/jitc-2021-004307
Oncolytic parainfluenza virus combines with NK cells to mediate killing of infected and non-infected lung cancer cells within 3D spheroids: role of type I and type III interferon signaling
Namita Varudkar, Jeremiah L Oyer, Alicja Copik, Griffith D Parks

Journal for ImmunoTherapy of Cancer Jun 2021, 9 (6) e002373; DOI: 10.1136/jitc-2021-002373
Natural killer T cell immunotherapy combined with oncolytic vesicular stomatitis virus or reovirus treatments differentially increases survival in mouse models of ovarian and breast cancer metastasis
Simon Gebremeskel, Adam Nelson, Brynn Walker, Tora Oliphant, Lynnea Lobert, Douglas Mahoney, Brent Johnston

Journal for ImmunoTherapy of Cancer Mar 2021, 9 (3) e002096; DOI: 10.1136/jitc-2020-002096
Combination immunotherapy using G-CSF and oncolytic virotherapy reduces tumor growth in osteosarcoma
Alvaro Morales-Molina, Stefano Gambera, Angela Leo, Javier García-Castro

Journal for ImmunoTherapy of Cancer Mar 2021, 9 (3) e001703; DOI: 10.1136/jitc-2020-001703
Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB–IVM1c melanoma
Josep Malvehy, Igor Samoylenko, Dirk Schadendorf, Ralf Gutzmer, Jean-Jacques Grob, Joseph J Sacco, Kevin S Gorski, Abraham Anderson, Cheryl A Pickett, Kate Liu, Helen Gogas

Journal for ImmunoTherapy of Cancer Mar 2021, 9 (3) e001621; DOI: 10.1136/jitc-2020-001621
Oncolytic vaccinia virus delivering tethered IL-12 enhances antitumor effects with improved safety
Yan Ge, Haiyan Wang, Jinghua Ren, Weilin Liu, Lingjuan Chen, Hongqi Chen, Junjie Ye, Enyong Dai, Congrong Ma, Songguang Ju, Zong Sheng Guo, Zuqiang Liu, David L Bartlett

Journal for ImmunoTherapy of Cancer Mar 2020, 8 (1) e000710; DOI: 10.1136/jitc-2020-000710
Initial dose of oncolytic myxoma virus programs durable antitumor immunity independent of in vivo viral replication
Erica B Flores, Bulent A Aksoy, Eric Bartee

Journal for ImmunoTherapy of Cancer Jun 2020, 8 (1) e000804; DOI: 10.1136/jitc-2020-000804
Oncolytic vesicular stomatitis virus–based cellular vaccine improves triple-negative breast cancer outcome by enhancing natural killer and CD8⁺ T-cell functionality
Seyedeh-Raheleh Niavarani, Christine Lawson, Marie Boudaud, Camille Simard, Lee-Hwa Tai

Journal for ImmunoTherapy of Cancer Mar 2020, 8 (1) e000465; DOI: 10.1136/jitc-2019-000465

Main menu

Oncolytic virotherapy

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Oncolytic virotherapy

Pages